State-of-the-art facility for commercial usage
The building is designed from an optimal pharmaceutical production process
HALIX's new building houses cGMP production rooms for the development and production of biopharmaceuticals. Production in the cleanrooms can take place here at BSL3 level (ML-III). EGM designed the high-tech building within the team of main contractor Kuijpers.
Research & development and production
The new five-level production facility measures 6,700 m2 and contains a state-of-the-art manufacturing line for viral vaccines and viral vectors, starting soon, with a 250 L bioreactor scale. A separate protein manufacturing area with a capacity up to 1,000 L single-use bioreactors is available. Laboratory spaces within the facility enable process development and transfer, analytical development and quality control of biopharmaceuticals.
The facility is a symbol for the strong innovative, dynamic and modern culture at HALIX
Alex Huybens, COO of HALIX
HALIX - bioscience as a service
HALIX is licensed for the contract manufacturing of clinical and commercial medicines according to Current Good Manufacturing Practice (cGMP) standards. As an end-to-end service provider, it will serve its customers the full range from the first development steps to start of commercial production after successful registration of products. The facility is designed and equipped according to latest biopharmaceutical quality standards. All cleanrooms are structured according to the unidirectional process flow of personal and materials and prepared for an BSL3 production, if required. The office spaces, laboratory and cleanroom areas offer up to 70 employees attractive and modern workplaces.
Partners
The new facility for HALIX has been realized by Kuijpers and its partners EGM architects, DuPrie Bouw, Cleanroom Combination Group en IMd Raadgevende Ingenieurs.
Photography: Kuijpers, EGM architects, Erika Gallegos